Department of Hepatobiliary Surgery, The First Affiliated Hospital of Wenzhou Medical College, 325000, Wenzhou, China.
Med Oncol. 2011 Dec;28(4):1012-6. doi: 10.1007/s12032-010-9600-6. Epub 2010 Jun 23.
Recently, two hepatic lineage markers epithelial cell adhesion molecule (EpCAM) and α-fetoprotein (AFP) were used to classify hepatocellular carcinoma (HCC) into four subtypes with prognostic implication. In the present study, we further evaluated the clinicopathologic and angiogenic characteristics among these HCC subtypes. EpCAM expression was investigated by immunohistochemistry in 115 HCC primary tumors. Based on EpCAM immunostaining and serum AFP levels, 115 HCC cases were classified into four subtypes: EpCAM+AFP+ (26.1%), EpCAM-AFP+ (20.0%), EpCAM+AFP- (20.8%), and EpCAM-AFP- (33.1%). EpCAM+AFP+ and EpCAM-AFP+ HCC were associated with late TNM stages and high frequencies of venous invasion, whereas EpCAM+AFP- and EpCAM-AFP- subtypes were associated with early TNM stages and low frequencies of venous invasion. Furthermore, EpCAM+AFP+ HCC had a significantly higher microvessel density (MVD) and higher level of VEGF (Vascular epithelial growth factor) expression than the other three subtypes. In conclusion, our study indicated that subtype classification of HCC based on EpCAM and AFP status had clinicopathologic and biologic implications in aggressive phenotype and angiogenesis. We also suggest that the EpCAM+AFP+ HCC patients might be potential therapeutic candidates for anti-angiogenesis therapy.
最近,两种肝系标志物上皮细胞黏附分子(EpCAM)和甲胎蛋白(AFP)被用于将肝细胞癌(HCC)分为具有预后意义的四个亚型。在本研究中,我们进一步评估了这些 HCC 亚型的临床病理和血管生成特征。通过免疫组织化学方法检测 115 例 HCC 原发性肿瘤中 EpCAM 的表达。基于 EpCAM 免疫染色和血清 AFP 水平,将 115 例 HCC 病例分为四组:EpCAM+AFP+(26.1%)、EpCAM-AFP+(20.0%)、EpCAM+AFP-(20.8%)和 EpCAM-AFP-(33.1%)。EpCAM+AFP+和 EpCAM-AFP+HCC 与晚期 TNM 分期和高静脉侵犯频率相关,而 EpCAM+AFP-和 EpCAM-AFP-亚型与早期 TNM 分期和低静脉侵犯频率相关。此外,EpCAM+AFP+HCC 的微血管密度(MVD)明显更高,VEGF(血管内皮生长因子)表达水平也更高。总之,我们的研究表明,基于 EpCAM 和 AFP 状态的 HCC 亚型分类在侵袭性表型和血管生成方面具有临床病理和生物学意义。我们还建议 EpCAM+AFP+HCC 患者可能是抗血管生成治疗的潜在治疗候选者。